Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

Expert Review of Clinical Immunology

Volumn 10, Issue 10, 2014, Pages 1309-1324

  Didier, Alain ^a   Wahn, Ulrich ^b   Horak, Friedrich ^c   Cox, Linda S ^d  

^a CHU RANGUEIL   (France)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Vienna Challenge Chamber   (Austria)

^d Allergy and Asthma Center   (United States)

Author keywords

5 grass pollen tablet; allergen specific immunotherapy; allergic rhinitis; allergic rhinoconjunctivitis; clinical trial; efficacy; pollinosis; safety; sublingual immunotherapy

Indexed keywords

GRASS POLLEN EXTRACT; ALLERGEN; TABLET;

ALLERGIC CONJUNCTIVITIS; ARTICLE; ASTHMA; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EAR PRURITUS; EYE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFESTATION; LYMPHADENOPATHY; MOUTH EDEMA; NEUROLOGIC DISEASE; ORAL PRURITUS; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLEN ALLERGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SENSITIZATION; SUBLINGUAL IMMUNOTHERAPY; SYMPTOMATOLOGY; TABLET; THROAT IRRITATION; TONGUE DISEASE; TONGUE PRURITUS; VASCULAR DISEASE; POACEAE; POLLEN; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; HUMANS; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL IMMUNOTHERAPY; TABLETS;

EID: 84907271067     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.957677     Document Type: Article

References (67)

1. Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician 2010;81:1440-6
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86): 8-160
3. Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 2012; 33(Suppl 1):S113-41
4. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84
5. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334
6. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis 2012;6:11-23
7. Moingeon P, Hrabina M, Bergmann KC, et al. Specific immunotherapy for common grass pollen allergies: Pertinence of a five grass pollen vaccine. Int Arch Allergy Immunol 2008;146:338-42
8. Valovirta E. EFA book on respiratory allergies. 2011. Available from: Www. theipcrg.org/download/attachments/689587/ EFABookonRespiratoryAllergiesFINAL.pdf? version=1&modificationDate=1332965739000 [Last accessed 2 April 2014]
9. Sih T, Mion O. Allergic rhinitis in the child and associated comorbidities. Pediatr Allergy Immunol 2010;21:e107-13
10. Uzzaman A, Story R. Chapter 5: Allergic rhinitis. Allergy Asthma Proc 2012;33 Suppl 1:S15-18
11. World Allergy Organization. WAO white book on allergy update 2013. World Allergy Organization; Milwaukee, WI: 2014
12. Kirmaz C, Aydemir O, Bayrak P, et al. Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2005;95:525-9
13. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008;29:600-8
14. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11:471-6
15. Williams DC, Edney G, Maiden B, Smith PK. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organ J 2013;6:4
16. Tsilochristou OA, Douladiris N, Makris M, Papadopoulos NG. Pediatric allergic rhinitis and asthma: Can the march be halted? Paediatr Drugs 2013;15:431-40
17. Turner PJ, Kemp AS. Allergic rhinitis in children. J Paediatr Child Health 2012;48: 302-10
18. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: From allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40:385-97
19. Incorvaia C. Preventive capacity of allergen immunotherapy on the natural history of allergy. J Prev Med Hyg 2013;54:71-4
20. Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: From mechanisms to meta-Analyses. Chest 2012;141:1303-14
21. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6
22. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-3
23. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936
24. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A systematic review. Laryngoscope 2014;124:616-27
25. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-74.e561-574
26. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
27. Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-Analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med 2014;12:71
28. Didier A, Malling HJ, Worm M, et al. Post-Treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568-77
29. Lyseng-Williamson KA. Sublingual five-grass pollen tablets (Oralair-): A guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drugs Ther Perspect 2014;doi; 10.1007/s40267-40014-40131-40267
30. ORALAIR-Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use: Food and Drug Administration Allergenic Products Advisory Committee Briefing Document. Stallergènes S.A., 2013. Available from: Www.fda.gov/ downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/ AllergenicProductsAdvisoryCommittee/ UCM377851.pdf [Last accessed 16 April 2014]
31. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: Location does not matter. J Allergy Clin Immunol Pract 2014;2:156-60
32. Pajno GB, Vita D, Caminiti L, et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005;116: 1380-1
33. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review. JAMA 2013;309:1278-88
34. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010(12):CD002893
35. Sublingual immunotherapy for allergic rhinitis. Creticos PS, 2014. Available from: Www.uptodate.com/contents/sublingualimmunotherapy-for-Allergic-rhinitis [Last accessed 10 May 2014]
36. Moingeon P, Peltre G, Bergmann KC. Rationale for a five-grass pollen vaccine. Clin Exp Allerg Rev 2008;8:12-14
37. Summary of Product Characteristics: Oralair-100 IR & 300 IR sublingual tablets. Stallergènes S.A., 2013. Available from: Http://www.stallergenes.com/ fileadmin/images/corporate/Emmanuelle/ Oralair-SmPC.pdf [Last accessed 1 September 2014]
38. US Prescribing Information: Oralair-(Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use. Stallergènes S.A., 2014. Available from: Http://oralair.com/docs/ ORALAIR%20Prescribing%20Information-Med%20Guide.pdf [Last accessed 11 May 2014]
39. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25
40. US Prescribing Information: Grastek-(Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use. ALK-Abello/ Merck, 2014. Available from: Http://www. merck.com/product/usa/pi-circulars/g/ grastek/grastek-pi.pdf [Last accessed 11 May 2014]
41. Kaul S, May S, Luttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy 2011;66:753-64
42. Chabre H, Gouyon B, Huet A, et al. Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: Implications for immunotherapy. Clin Exp Allergy 2010;40:505-19
43. Köberlein J, Mösges R. Oralair-: A causal treatment for grass pollen-induced allergic rhinoconjunctivitis. Immunotherapy 2013;5: 13-21
44. Hong J, Bielory L. Oralair-: Sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis. Expert Rev Clin Immunol 2011;7:437-44
45. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120: 1338-45
46. Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy 2014;44: 986-98
47. Hejl C, Wurtzen PA, Kleine-Tebbe J, et al. Phleum pratense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009;39:752-9
48. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: Practical implications for the clinician. J Allergy Clin Immunol Pract 2013;1:228-41
49. Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471-7
50. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
51. Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre-And coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66
52. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130:1327-34
53. Study NCT00803244: Safety and efficacy of Phase III study on 300 IR SLIT in patients suffering from grass pollen rhinoconjunctivitis (with or without asthma). Stallergènes S.A., 2011. Available at http://clinicaltrials.gov/show/ NCT00803244 [Last accessed 20 April 2014]
54. Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy-A phase-1 study. Allergy 2006;61:1173-6
55. Malling HJ, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009;39:387-93
56. Wahn U, Malling HJ, Cox LS, et al. Efficacy of 300IR 5-grass pollen extract sublingual tablet assessed by daily combined score: Results of three double-blind placebocontrolled natural field studies in children/ adolescents and adults. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
57. Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 2012;67:321-7
58. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24
59. Karagiannis E, et al. Non-interventional 2-year-study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen. Presented at Pediatric Allergy & Asthma Meeting (PAAM); Athens, Greece; 2013
60. Karagiannis E, Hadler M, Shah-Hosseini K, et al. Full symptom control in patients with allergic rhinoconjunctivitis caused by grass pollen-results of a 2-year sublingual allergen immunotherapy (AIT) study. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
61. Karagiannis E, Hadler M, Shah-Hosseini K, et al. Non-interventional 2-year study of sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by grass pollen. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
62. Antolin D, Valbuena T, Valls A, et al. One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
63. Fernandez-Nieto M, Alvarez JA, Alvarado MI, et al. What is the opinion of the patients under 5 grass pollen tablets immunotherapy? First season assessment in adults. Findings of the SMILE study. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
64. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: Efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010;21:970-6
65. Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: An indirect analysis of efficacy, safety and cost. J Eval Clin Pract 2014;20:225-38
66. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012;15:906-17
67. Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin Drug Investig 2013;33:343-9